Two novel polyoxometalates containing pharmaceutical component amantadine, formulated with (C10H18N) 5PMo12O40Cl2 5H2O (I) and (C10H18N) 6As2Mo18O62 6CH3CN 6H2O (II) were first synthesized and characterized by IR, UV-...Two novel polyoxometalates containing pharmaceutical component amantadine, formulated with (C10H18N) 5PMo12O40Cl2 5H2O (I) and (C10H18N) 6As2Mo18O62 6CH3CN 6H2O (II) were first synthesized and characterized by IR, UV-Vis spectra and X-ray diffraction. Structural analyses of I and II suggested that polyanions in these compounds were reserved their Keggin or Dawson structures and were linked to amantadine through electrostatic interaction and hydrogen bonding.展开更多
文摘Two novel polyoxometalates containing pharmaceutical component amantadine, formulated with (C10H18N) 5PMo12O40Cl2 5H2O (I) and (C10H18N) 6As2Mo18O62 6CH3CN 6H2O (II) were first synthesized and characterized by IR, UV-Vis spectra and X-ray diffraction. Structural analyses of I and II suggested that polyanions in these compounds were reserved their Keggin or Dawson structures and were linked to amantadine through electrostatic interaction and hydrogen bonding.
